TACH-101 is under clinical development by Tachyon Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TACH-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TACH-101 overview

TACH-101 (formerly QC8222) is under development for the treatment of solid tumors including advanced or metastatic cancer, metastatic colorectal cancer (CRC), esophageal cancer, gastric cancer, breast cancer, triple-negative breast cancer and Diffuse large B-cell lymphomas including germinal-center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL). It is administered through oral route. The drug candidate acts as pan-KDM4 epigenetic regulator.

Tachyon Therapeutics overview

Tachyon Therapeutics is a biotechnology company involved in therapeutics for the treatment of advanced cancers. Tachyon Therapeutics is headquartered in Houston, Texas, the US.

For a complete picture of TACH-101’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.